- Home
- NXTC vs NERV Comparison
NXTC vs NERV Comparison
Compare NXTC & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- NERV
- Stock Information
- Founded
- NXTC 2015
- NERV 2007
- Country
- NXTC United States
- NERV United States
- Employees
- NXTC N/A
- NERV N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- NERV Health Care
- Exchange
- NXTC Nasdaq
- NERV Nasdaq
- Market Cap
- NXTC 13.9M
- NERV 12.0M
- IPO Year
- NXTC 2019
- NERV 2014
- Fundamental
- Price
- NXTC $6.17
- NERV $2.13
- Analyst Decision
- NXTC Strong Buy
- NERV Hold
- Analyst Count
- NXTC 3
- NERV 1
- Target Price
- NXTC $33.00
- NERV $5.00
- AVG Volume (30 Days)
- NXTC 299.6K
- NERV 20.2K
- Earning Date
- NXTC 08-04-2025
- NERV 08-05-2025
- Dividend Yield
- NXTC N/A
- NERV N/A
- EPS Growth
- NXTC N/A
- NERV N/A
- EPS
- NXTC N/A
- NERV 0.83
- Revenue
- NXTC N/A
- NERV N/A
- Revenue This Year
- NXTC N/A
- NERV N/A
- Revenue Next Year
- NXTC N/A
- NERV N/A
- P/E Ratio
- NXTC N/A
- NERV $2.61
- Revenue Growth
- NXTC N/A
- NERV N/A
- 52 Week Low
- NXTC $2.69
- NERV $1.15
- 52 Week High
- NXTC $20.76
- NERV $3.30
- Technical
- Relative Strength Index (RSI)
- NXTC 62.21
- NERV 66.09
- Support Level
- NXTC $4.75
- NERV $1.94
- Resistance Level
- NXTC $5.23
- NERV $2.32
- Average True Range (ATR)
- NXTC 0.56
- NERV 0.15
- MACD
- NXTC 0.10
- NERV 0.03
- Stochastic Oscillator
- NXTC 86.74
- NERV 73.38
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.